Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|September 1, 2008
Formulary Digital Edition September 2008
Potentially inappropriate medication use in hospitalized older adults: A DUE using the full Beers criteria; Focus on alogliptin; Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Pope Leo XIV's lung cancer diagnosis puts a spotlight on low U.S. screening rates
2
Chronic hand eczema needs more than topical steroids | Fall Clinical Derm 2026
3
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
4
U.S. employer-covered healthcare costs: It’s still the prices
5